March 11, 2021 – Ardigen, a global leader in artificial intelligence for drug discovery, is proud to announce that Dr. Michał Warchoł has joined the company’s Board of Management as its 4th member. He brings extensive knowledge and experience in the field, which is strategic for Ardigen’s development.
Dr. Warchoł will continue his mission as General Director of the Biomedical Imaging Business Unit at Ardigen, where he coordinates business activities focused on leveraging AI in biomedical imaging applied in the drug discovery process.
Dr. Warchoł joined Ardigen in 2016 to build Data Science and Machine learning capabilities and expertise within Ardigen AI Labs. He earned a PhD in statistics at the Institute of Statistics, Biostatistics and Actuarial Sciences at Université Catholique de Louvain in Belgium. Part of his research program was conducted at the Department of Statistics at Columbia University in New York. He also holds a master’s degree in Mathematics and a bachelor’s degree in Finance. Prior to joining Ardigen, Dr. Warchoł co-founded DeepArt UG, a company providing novel image processing algorithms.
Recent breakthroughs in computer vision as well as imaging technologies are proving to be instrumental in both clinical, as well as discovery stages of the drug discovery process. As a board member, I will be responsible for the Biomedical Imaging Business Unit with the aim to develop Ardigen’s strong position in this rapidly growing market – comments Dr. Michał Warchoł
By joining the Ardigen Management Board, Dr. Michał Warchoł will strengthen the Company’s position as a leader in the global AI field of Drug Discovery market. This is an important step towards the implementation of the Company’s long-term strategy, in which the unique combination of AI competencies and molecular biology plays a key role – said Janusz Homa, Ardigen CEO
